The Benefits of Enhanced Terminal Room-Disinfection (BETR-D) study, the most comprehensive study on UV disinfection to date, was a cluster randomized, multicenter crossover study with 2×2 factorial design to evaluate the impact of enhanced terminal room disinfection on acquisition and infection caused by multidrug-resistant organisms (MDROs). The two-year, $2M, CDC-funded study

Adding ultraviolet-C light disinfection to standard terminal room disinfection practices can reduce transmission drug-resistant organisms by a cumulative 30 percent, according to a study led by Duke Health and published in The Lancet. The trial took place from 2012 to 2014 at nine hospitals — three Duke University Health System

From Duke Health: DURHAM, N.C. — A new tool — a type of ultraviolet light called UVC — could aid hospitals in the ongoing battle to keep drug-resistant bacteria from lingering in patient rooms and causing new infections. Some hospitals have already begun using UVC machines in addition to standard

The pioneer in no-touch UV disinfection has now been validated by a CDC-funded randomized clinical trial. Tru-D SmartUVC, short for “total room ultraviolet disinfection,” was the device of choice for the Benefits of Enhanced Terminal Room-Disinfection (BETR-D) study which was recently published in The Lancet. The BETR-D study proves that